Related Experiment Videos
[Tumor markers for hepatocellular carcinoma]
S Fujiyama1, M Tanaka, S Maeda
1Third Dept. of Internal Medicine, Kumamoto University School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 1, 2001
Summary
Early detection of hepatocellular carcinoma (HCC) relies on combining complementary tumor markers and imaging. Regular screening of high-risk patients identifies HCC sooner, aiding timely treatment and relapse detection.
Area of Science:
- Hepatology
- Oncology
- Biomarker Research
Context:
- Hepatocellular carcinoma (HCC) diagnosis relies on serological tumor markers (alpha-fetoprotein, L3%, PIVKA-II) and imaging.
- These diagnostic methods are complementary, not correlated, necessitating a combined approach.
- Identifying high-risk individuals (chronic hepatitis, liver cirrhosis) is crucial for early detection.
Purpose:
- To emphasize the complementary nature of serological tumor markers and imaging in HCC diagnosis.
- To highlight the importance of regular screening for high-risk populations.
- To establish the role of tumor markers in early HCC detection and relapse surveillance.
Summary:
- Combining serological tumor markers (alpha-fetoprotein, L3%, PIVKA-II) with imaging improves hepatocellular carcinoma (HCC) diagnosis.
- Regular screening of high-risk patients (chronic hepatitis, liver cirrhosis) with tumor markers can detect HCC earlier than imaging alone.
- Serological markers are vital for identifying HCC recurrence and guiding therapeutic interventions.
Impact:
- Facilitates earlier diagnosis of hepatocellular carcinoma (HCC), improving patient outcomes.
- Enables more accurate evaluation of HCC treatment efficacy.
- Provides a valuable tool for monitoring HCC patients and detecting disease relapse.